SLC5A5 and neoplasm: In the context of OS, agents such as VCN-01, Delta-24-ACT, and VSV-IFNβ-NIS have significantly suppressed tumor growth and extended survival in preclinical models (6, 17), offering a compelling foundation for further translational development.